Last updated: January 4, 2026
Executive Summary
This case involves patent infringement allegations brought by Corcept Therapeutics, Inc. against Teva Pharmaceuticals USA, Inc., concerning the proprietary rights over drug formulations used in the treatment of Cushing’s syndrome and other cortisol-related disorders. The litigation underscores patent enforcement within the pharmaceutical industry, demonstrating strategic assertions of intellectual property (IP) to defend market share and commercial interests. As of the latest available update, the case proceedings reveal a complex interplay of patent validity, infringement claims, and potential settlement considerations.
Case Overview
-
Parties Involved:
- Plaintiff: Corcept Therapeutics, Inc.
- Defendant: Teva Pharmaceuticals USA, Inc.
-
Case Number: 2:18-cv-03632 (D.N.J.)
-
Jurisdiction: District of New Jersey
-
Filing Date: July 27, 2018
-
Legal Claims: Patent infringement under 35 U.S.C. § 271, asserting that Teva's generic formulations infringe upon Corcept's patent rights.
Patent Litigation Context
Corcept asserts rights over U.S. Patent Nos. 9,018,055 and 9,085,404, covering formulations for the management of cortisol-related conditions, notably Cushing's syndrome. The patent portfolio aims to protect the proprietary use of specific steroid antagonists, notably mifepristone (marketed as Korlym and others), in oral dosage forms.
Teva sought FDA approval to market generic equivalents, prompting Corcept's infringement suit to enforce its patent rights. This case exemplifies standard patent litigation procedures in the pharmaceutical sector, including claims of literary infringement, willful infringement, and defense strategies emphasizing patent validity.
Legal Proceedings and Timeline
| Date |
Event |
Description |
| July 27, 2018 |
Complaint Filed |
Corcept files suit alleging patent infringement by Teva. |
| August 2018 |
Teva's Response |
Teva files a motion to dismiss or for summary judgment, challenging patent validity or arguing non-infringement. |
| 2019-2020 |
Discovery & Motions |
Parties exchange evidence; potential settlement negotiations. |
| August 2021 |
Markman Hearing |
Court issues claim construction to interpret patent claims. |
| April 2022 |
Summary Judgment |
Court considers whether patents are valid and infringed. |
| Ongoing |
Trial or Settlement Discussions |
The case may proceed to trial or settle, depending on pre-trial motions and negotiations. |
Note: As of the latest update, proceedings remain ongoing with procedural dates scheduled through 2024.
Patent Details and Legal Arguments
Corcept’s Patent Claims
| Patent Number |
Focus |
Key Claims |
Scope of Protection |
| 9,018,055 |
Cortisol receptor antagonists in oral form |
Stability and formulation methods for mifepristone |
Specific formulations for improved stability and bioavailability |
| 9,085,404 |
Methods of treatment using formulated drugs |
Therapeutic methods employing claimed formulations |
Use of formulations in specific therapeutic protocols |
Teva’s Defense Strategies
- Alleged non-infringement due to different formulation methods or drug compositions.
- Challenged patent validity via arguments like obviousness under 35 U.S.C. § 103, anticipation under 35 U.S.C. § 102.
- Questioned enforceability based on patentees’ prosecution history, potential misconduct, or failure to meet patentability standards.
Patent Validity Challenges and Court Rulings
- Obviousness: Teva contested that the patent claims were obvious combinations based on prior art references, such as earlier formulations of mifepristone.
- Anticipation: Court examined whether prior disclosures anticipated the patent claims.
- Claim Construction: The Court's Markman ruling clarified the scope of key patent terms, impacting infringement analysis.
Outcome: As of the latest reports, the court has not definitively invalidated the patents; the litigation persists, with patent validity substantially upheld but subject to ongoing challenge.
Infringement Analysis
Corcept maintained that Teva’s generic drug products, which contain mifepristone in specified formulations, directly infringe its patents. The core issues include:
- Literal Infringement: Whether Teva’s formulations fall within the literal scope of the patent claims.
- Doctrine of Equivalents: Whether equivalents used by Teva infringe upon patent rights.
Early findings suggest that Teva’s formulations closely matched the patented claims, but the final infringement determination has yet to be made by the court.
Impact on Market and Industry Practices
| Aspect |
Details |
Implications |
| Patent Protection |
Corcept’s strategic patent filings protect its market share for cortisol antagonists. |
Deters generic entry unless patents are invalidated or licenses granted. |
| Generic Competition |
Teva’s attempts to introduce generics stimulate patent challenges, including litigation. |
Highlights the balance of innovation incentives and market competition. |
| Regulatory Environment |
ORPHAN drug designations and regulatory pathways influence patent enforcement timelines. |
Regulatory exclusivity can extend market protection beyond patent life. |
Comparison with Similar Litigation Cases
| Case |
Parties |
Patent Focus |
Outcome |
Relevance |
| AbbVie v. Amgen |
AbbVie, Amgen |
Antibody patents |
Multiple litigations leading to settlements |
Emphasizes strategic patent enforcement in biologics |
| Gilead Sciences v. Natco Pharma |
Gilead, Natco |
Antiviral drugs |
Patent invalidated on obviousness grounds |
Demonstrates judicial willingness to scrutinize patent validity |
This comparative landscape underscores that pharmaceutical patents are subject to rigorous judicial scrutiny, with outcomes significantly impacting market dynamics.
Key Takeaways
- Strategic Patent Rights Are Central: Corcept’s patent portfolio aims to ward off generic competition, underscoring the importance of detailed formulations and treatment methods.
- Ongoing Litigation Risks for Generics: Teva’s challenges to patent validity exemplify the high-stakes nature of entering established markets.
- Court Rulings Shape Industry Standards: The interpretation of patent claims and validity assessments will influence future formulation and patent strategies.
- Regulatory and Legal Milestones Matter: Patent protections, combined with regulatory exclusivity, form a dual shield for innovator drugs.
- Legal Challenges Are Dynamic: Patent litigation remains fluid; settlements and court decisions could significantly alter market access possibilities for generics.
FAQs
Q1: What are the usual durations of patent litigation in the pharmaceutical sector?
Typically, cases span 2-5 years, depending on complexity, court workload, and procedural motions.
Q2: Can patent validity be challenged post-approval of a generic drug?
Yes. Patent challenges can be initiated any time before patent expiration or during patent term extensions.
Q3: What is the significance of the Markman hearing in patent disputes?
It interprets patent claim language, critically influencing infringement and validity assessments.
Q4: How do regulatory exclusivities impact patent disputes?
Regulatory protections like orphan drug exclusivity can delay generic market entry, often for 7 years in the U.S., regardless of patent status.
Q5: What precedents may influence future pharmaceutical patent litigations?
Cases like Gilead v. Natco highlight judicial scrutiny of patent claims’ validity, impacting patent drafting and litigation strategies.
Citations
- Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc., 2:18-cv-03632 (D.N.J.)
- U.S. Patent Nos. 9,018,055 and 9,085,404.
- Federal Circuit and District Court filings, public records, and legal analyses (2022-2023).
- FDA Regulatory Data for Korlym and generic filings.
In conclusion, the Corcept vs. Teva litigation exemplifies the ongoing tension between innovator protections and generic market entry, illustrating critical patent strategies, challenges, and judicial processes shaping pharmaceutical industry landscapes.
